Follicle‑stimulating hormone receptor gene polymorphisms of ovarian reserve markers in Romanian population

Association between phenotype and follicle-stimulating hormone (FSH) receptor and FSH beta chain genotype was evaluated in women with ovarian dysfunction. FSH receptor gene single nucleotide polymorphisms (SNPs) were analyzed by restricted fragment length polymorphism (RFLP) technique. Three groups...

Full description

Saved in:
Bibliographic Details
Published inExperimental and therapeutic medicine Vol. 20; no. 6; p. 1
Main Authors Tanase, Adina-Elena, Nemescu, Dragos, Popescu, Roxana, Carauleanu, Alexandru, Mogos, Raluca Anamaria, Luca, Alexandru, Onofriescu, Mircea
Format Journal Article
LanguageEnglish
Published Athens Spandidos Publications 01.12.2020
Spandidos Publications UK Ltd
D.A. Spandidos
Subjects
Deoxyribonucleic acid
Diagnosis
DNA
Endometriosis
Follicle-stimulating hormone
Genetic aspects
Genetic markers
Health aspects
In vitro fertilization
Mutation
Obstetrical research
Ovarian diseases
Ovaries
Patients
Polymorphism
Single nucleotide polymorphisms
Statistical analysis
Ultrasonic imaging
Romania
Online AccessGet full text

Cover

More Information
Summary:Association between phenotype and follicle-stimulating hormone (FSH) receptor and FSH beta chain genotype was evaluated in women with ovarian dysfunction. FSH receptor gene single nucleotide polymorphisms (SNPs) were analyzed by restricted fragment length polymorphism (RFLP) technique. Three groups were analyzed: two groups formed of poor responders (women with ovarian dysfunctions caused by endometriosis and patients who underwent ovarian stimulation protocols) and a third good responders group (normal-ovulatory women who gave birth to naturally conceived children). A higher average level of basal FSH values were found in mutants in the A919G/Ala307Thr/rs6165 or A2039G/Asn680Ser/rs6166 tests (7.16[+ or -]1.09; P=0.659). Anti-mullerian hormone (AMH) below 1.2 ng/ml was associated with a higher frequency of mutations: 33.3% A919G/Ala307Thr and A2039G/Asn680Ser (P=0.137) and also in 66.6% FSH receptor less frequent polymorphism (c.-29G>A) rs 1394205 (P=0.522). The age, day 3 FSH, and AMH levels are widely used to investigate female infertility. However, we have not yet found the ideal biomarker to determine the best outcome and treatment plan for our patients. We cconsider that genetic markers will become the future in the personalization of controlled ovarian stimulation treatment in the upcoming period. Key words: infertility, follicle, estradiol, prolactin, progesterone, polymorphism
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2020.9333